Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
DUBLIN, Ireland and TREVOSE, Pa., Feb. 24, 2017 -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company will hold its Annual General Meeting (AGM) of Shareholders on Thursday, May 11, 2017 at the offices of Arthur Cox, Earlsfort Terrace, Dublin, Ireland. The Company will announce the time of the AGM at a later date. The record date for shareholders entitled to receive notice of and vote at the AGM is Wednesday, March 22, 2017.
About Strongbridge Biopharma
Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit www.strongbridgebio.com.
Contacts Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations The Trout Group Marcy Nanus +1 646-378-2927 [email protected] USA 900 Northbrook Drive Suite 200 Trevose, PA 19053 Tel. +1 610-254-9200 Fax. +1 215-355-7389
